InvestorsObserver
×
News Home

Is aTyr Pharma Inc (LIFE) the Top Pick in the Biotechnology Industry?

Wednesday, December 16, 2020 11:26 AM | InvestorsObserver Analysts

Mentioned in this article

Is aTyr Pharma Inc (LIFE) the Top Pick in the Biotechnology Industry?

A rating of 77 puts aTyr Pharma Inc (LIFE) near the top of the Biotechnology industry according to InvestorsObserver. aTyr Pharma Inc's score of 77 means it scores higher than 77% of stocks in the industry. aTyr Pharma Inc also received an overall rating of 62, putting it above 62% of all stocks. Biotechnology is ranked 25 out of the 148 industries.

Overall Score - 62
LIFE has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on LIFE!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With aTyr Pharma Inc Stock Today?

aTyr Pharma Inc (LIFE) stock has fallen -1.89% while the S&P 500 has risen 0.1% as of 11:10 AM on Wednesday, Dec 16. LIFE is down -$0.08 from the previous closing price of $4.37 on volume of 89,629 shares. Over the past year the S&P 500 has risen 15.84% while LIFE has risen 7.25%. LIFE lost -$2.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on aTyr Pharma Inc (LIFE) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App